XML 26 R14.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 6 - Stock-based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2024
Notes to Financial Statements |
Shareholders' Equity and Share-Based Payments [Text Block] | Note 6 – Stock-Based Compensation We recorded non-cash stock compensation expense in each period as follows:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |
Stock options |  | $ | 640 |  |  | $ | 522 |
Restricted stock |  |  | 58 |  |  |  | 6 |
Total |  | $ | 698 |  |  | $ | 528 |
We have various stock-based employee compensation plans, for which compensation cost is recognized in the financial statements. The cost is measured at the grant date, based on the estimated fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity award). Our stockholders have approved various equity-based plans that permit the grant of stock options, restricted stock and other equity-based awards. In addition, our stockholders have approved the grant of stock options outside of these plans. On July 16, 2024, our stockholders approved the 2024 Long-Term Incentive Plan (“2024 LTIP”) as the successor plan to the 2014 Long-Term Incentive Plan (“2014 LTIP”) that expired on June 2, 2024. Under the 2024 LTIP, a total of 2,000,000 shares of common stock were made available for grant of awards.. Of the total number of shares of common stock available for awards under the 2024 LTIP, no more than 800,000 shares of common stock may be used for awards other than stock options and stock appreciation rights. Grants under the 2024 LTIP may be awarded through July 15, 2034. Stock options granted under the 2024 LTIP and 2014 LTIP are either Incentive Stock Options (“ISOs”) or Non-Qualified Stock Options (“NQSOs”). Key employees are eligible to receive ISOs and NQSOs; however, directors and consultants are eligible to receive only NQSOs. Stock options vest in equal installments on the first, second and third anniversaries of the grant date and expire on the seventh anniversary of the grant date. As of December 31, 2024, there were 258,060 stock options outstanding under the 2024 LTIP and 848,376 stock options outstanding under the 2014 LTIP. As of December 31, 2024, there was $1,108 of total unrecognized compensation costs related to outstanding stock options, which we expect to recognize over a weighted average period of 2.1 years. We use the Black-Scholes option-pricing model to estimate fair value of stock-based awards. The following weighted average assumptions were used to value options granted during the years ended December 31, 2024 and 2023:
|  | Year ended December 31, |
|  | 2024 |  |  | 2023 |
Risk-free interest rate |  |  | 4.3 | % |  |  | 4.1 | %
Volatility factor |  |  | 58 | % |  |  | 57 | %
Weighted average expected life (years) |  |  | 4.7 |  |  |  | 4.9 |
Forfeiture rate |  |  | 10.0 | % |  |  | 10.0 | %
Dividends |  |  | 0.0 | % |  |  | 0.0 | %
We calculate expected volatility for stock options by taking an average of historical volatility over the expected term. The computation of expected term was determined based on historical experience of similar awards and consideration of the contractual terms of the stock-based awards and vesting schedules. The interest rate for periods within the contractual life of the award is based on the U.S. Treasury yield in effect at the time of grant. Forfeiture rates are calculated by dividing unvested shares forfeited by beginning shares outstanding. The pre-vesting forfeiture rate is calculated yearly and is determined based on historical experience. The following tables summarize data for the stock options issued by us:
Year ended December 31, 2024 |
|  | Number of shares |  |  | Weighted average exercise price per share |  |  | Weighted average remaining contractual term |  |  | Aggregate intrinsic value |
Shares under option – January 1 |  |  | 1,250,595 |  |  | $ | 7.10 |  |  |  |  |  |  |  |  |
Options granted |  |  | 261,520 |  |  |  | 7.85 |  |  |  |  |  |  |  |  |
Options exercised |  |  | (298,293 | ) |  |  | 7.08 |  |  |  |  |  |  |  |  |
Options forfeited or expired |  |  | (107,386 | ) |  |  | 8.41 |  |  |  |  |  |  |  |  |
Shares under option – December 31 |  |  | 1,106,436 |  |  | $ | 7.15 |  |  |  | 4.53 |  |  | $ | 741 |
Vested and expected to vest - December 31 |  |  | 1,003,942 |  |  | $ | 7.17 |  |  |  | 4.36 |  |  | $ | 674 |
Options exercisable – December 31 |  |  | 625,826 |  |  | $ | 7.18 |  |  |  | 3.18 |  |  | $ | 477 |
Year ended December 31, 2023 |
|  | Number of shares |  |  | Weighted average exercise price per share |
Shares under option – January 1 |  |  | 1,425,693 |  |  | $ | 6.72 |
Options granted |  |  | 231,650 |  |  |  | 6.69 |
Options exercised |  |  | (254,393 | ) |  |  | 5.83 |
Options forfeited or expired |  |  | (152,355 | ) |  |  | 5.06 |
Shares under option – December 31 |  |  | 1,250,595 |  |  | $ | 7.10 |
Options exercisable – December 31 |  |  | 789,209 |  |  | $ | 7.56 |
The following table represents additional information about stock options outstanding at December 31, 2024:
|  |  |  | Option outstanding |  |  | Options exercisable |
Range of exercise prices |  | Number of outstanding options |  |  | Weighted- average remaining contractual life |  |  | Weighted- average exercise price |  |  | Number of options exercisable |  |  | Weighted- average exercise price |
$4.07 | - | $6.51 |  |  | 316,702 |  |  |  | 4.01 |  |  | $ | 5.68 |  |  |  | 235,589 |  |  | $ | 5.83 |
$6.84 | - | $6.97 |  |  | 317,594 |  |  |  | 5.21 |  |  |  | 6.88 |  |  |  | 176,157 |  |  |  | 6.92 |
$7.86 | - | $7.86 |  |  | 258,060 |  |  |  | 6.95 |  |  |  | 7.86 |  |  |  | 0 |  |  |  | 0 |
$8.25 | - | $9.85 |  |  | 214,080 |  |  |  | 1.37 |  |  |  | 8.89 |  |  |  | 214,080 |  |  |  | 8.89 |
$4.07 | - | $9.85 |  |  | 1,106,436 |  |  |  | 4.53 |  |  | $ | 7.15 |  |  |  | 625,826 |  |  | $ | 7.18 |
The weighted average fair value of options granted during the years ended December 31, 2024 and 2023 was $4.08 and $3.48, respectively. The total intrinsic value of options (which is the amount by which the stock price exceeded the exercise price of the options on the date of exercise) exercised during the years ended December 31, 2024 and 2023 was $1,007 and $556, respectively. Cash received from stock option exercises under our stock-based compensation plans for the years ended December 31, 2024 and 2023 was $1,999 and $1,248, respectively. Restricted stock awards vest in equal annual installments over three years. The Company granted restricted stock awards of 35,700 shares and 4,029 shares for the years ended December 31, 2024 and 2023, respectively. The average grant date fair value of restricted stock awards was $8.71 and $7.45 for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, there was $280 of total unrecognized compensation costs related to outstanding restricted shares. There were 1,707,440 shares of common stock available for future issuance under equity compensation plans as of December 31, 2024.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration